Acid alpha-glucosidase deficiency (Pompe disease)

Tokiko Fukuda, Ashley Roberts, Paul H. Plotz, Nina Raben

Research output: Contribution to journalArticle

Abstract

The development and recent approval of recombinant acid alpha-glucosidase for enzyme replacement therapy have been major milestones in Pompe disease research. Acid alpha-glucosidase is the enzyme responsible for degradation of glycogen polymers to glucose in the acidic milieu of the lysosomes. Cardiac and skeletal muscles are the two major tissues affected by the accumulation of glycogen within the lysosomes. Both cardiomyopathy and skeletal muscle myopathy are observed in patients with complete enzyme deficiency; this form of the disease is fatal within the first year of life. Skeletal muscle myopathy eventually leading to respiratory insufficiency is the predominant manifestation of partial enzyme deficiency. The recombinant enzyme alglucosidase alfa is the first drug ever approved for this devastating disorder. This review discusses the benefits and the shortcomings of the new therapy.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalCurrent Neurology and Neuroscience Reports
Volume7
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Glycogen Storage Disease Type II
Deficiency Diseases
Skeletal Muscle
alpha-Glucosidases
Muscular Diseases
Enzymes
Lysosomes
Glycogen
Enzyme Replacement Therapy
Acids
Glucans
Cardiomyopathies
Respiratory Insufficiency
Myocardium
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Acid alpha-glucosidase deficiency (Pompe disease). / Fukuda, Tokiko; Roberts, Ashley; Plotz, Paul H.; Raben, Nina.

In: Current Neurology and Neuroscience Reports, Vol. 7, No. 1, 01.2007, p. 71-77.

Research output: Contribution to journalArticle

Fukuda, Tokiko ; Roberts, Ashley ; Plotz, Paul H. ; Raben, Nina. / Acid alpha-glucosidase deficiency (Pompe disease). In: Current Neurology and Neuroscience Reports. 2007 ; Vol. 7, No. 1. pp. 71-77.
@article{83c219f53ad24b0396b50274c5dd5673,
title = "Acid alpha-glucosidase deficiency (Pompe disease)",
abstract = "The development and recent approval of recombinant acid alpha-glucosidase for enzyme replacement therapy have been major milestones in Pompe disease research. Acid alpha-glucosidase is the enzyme responsible for degradation of glycogen polymers to glucose in the acidic milieu of the lysosomes. Cardiac and skeletal muscles are the two major tissues affected by the accumulation of glycogen within the lysosomes. Both cardiomyopathy and skeletal muscle myopathy are observed in patients with complete enzyme deficiency; this form of the disease is fatal within the first year of life. Skeletal muscle myopathy eventually leading to respiratory insufficiency is the predominant manifestation of partial enzyme deficiency. The recombinant enzyme alglucosidase alfa is the first drug ever approved for this devastating disorder. This review discusses the benefits and the shortcomings of the new therapy.",
author = "Tokiko Fukuda and Ashley Roberts and Plotz, {Paul H.} and Nina Raben",
year = "2007",
month = "1",
doi = "10.1007/s11910-007-0024-4",
language = "English (US)",
volume = "7",
pages = "71--77",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Acid alpha-glucosidase deficiency (Pompe disease)

AU - Fukuda, Tokiko

AU - Roberts, Ashley

AU - Plotz, Paul H.

AU - Raben, Nina

PY - 2007/1

Y1 - 2007/1

N2 - The development and recent approval of recombinant acid alpha-glucosidase for enzyme replacement therapy have been major milestones in Pompe disease research. Acid alpha-glucosidase is the enzyme responsible for degradation of glycogen polymers to glucose in the acidic milieu of the lysosomes. Cardiac and skeletal muscles are the two major tissues affected by the accumulation of glycogen within the lysosomes. Both cardiomyopathy and skeletal muscle myopathy are observed in patients with complete enzyme deficiency; this form of the disease is fatal within the first year of life. Skeletal muscle myopathy eventually leading to respiratory insufficiency is the predominant manifestation of partial enzyme deficiency. The recombinant enzyme alglucosidase alfa is the first drug ever approved for this devastating disorder. This review discusses the benefits and the shortcomings of the new therapy.

AB - The development and recent approval of recombinant acid alpha-glucosidase for enzyme replacement therapy have been major milestones in Pompe disease research. Acid alpha-glucosidase is the enzyme responsible for degradation of glycogen polymers to glucose in the acidic milieu of the lysosomes. Cardiac and skeletal muscles are the two major tissues affected by the accumulation of glycogen within the lysosomes. Both cardiomyopathy and skeletal muscle myopathy are observed in patients with complete enzyme deficiency; this form of the disease is fatal within the first year of life. Skeletal muscle myopathy eventually leading to respiratory insufficiency is the predominant manifestation of partial enzyme deficiency. The recombinant enzyme alglucosidase alfa is the first drug ever approved for this devastating disorder. This review discusses the benefits and the shortcomings of the new therapy.

UR - http://www.scopus.com/inward/record.url?scp=33846652453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846652453&partnerID=8YFLogxK

U2 - 10.1007/s11910-007-0024-4

DO - 10.1007/s11910-007-0024-4

M3 - Article

C2 - 17217857

AN - SCOPUS:33846652453

VL - 7

SP - 71

EP - 77

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

ER -